Lyon, France, June 30, 2023 – POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announces that the Autorité des Marchés Financiers (AMF) today approved a prospectus for the admission of new shares of the Company already issued or to be issued upon redemption of bonds redeemable in shares (ORA) or bonds redeemable in ordinary shares new or existing (ORANE) of the Company, in circulation or to be issued, following the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.
To receive information from POXEL in real time, send a request to [email protected].